Hodgkin Lymphoma Journal Articles

Progression of Hodgkin Lymphoma and Plasma Cell Neoplasms This case-based report reviews the clinical presentation, morphologic, and molecular findings in 20 cases of Hodgkin lymphoma and plasma cell neoplasms and their subsequent progression.
American Journal of Clinical Pathology, July 06, 2023
A Promising Immunotherapy Against Small Cell Lung Cancer This editorial provides commentary on the results from a study investigating the potential of a promising new targeted therapy for small cell lung cancer.
Translational Lung Cancer Research, July 05, 2023
Progression of Follicular Lymphoma and Related Entities Review the morphologic, immunophenotypic, and molecular features of transformations from indolent B-cell lymphomas to aggressive lymphomas in this report.
American Journal of Clinical Pathology, June 22, 2023
Strategies to Overcome Resistance to ALK Inhibitors in NSCLC Certain patients with ALK-positive lung cancer may experience drug resistance to ALK-targeted therapy. What are the options?
Translational Lung Cancer Research, May 22, 2023
Risks of Second Non-Breast Primaries Following Breast Cancer A better understanding of the potential risks of developing second primary malignancies among survivors of breast cancer could lead to better prevention and management strategies for these patients.
Breast Cancer Research, May 05, 2023
Pulmonary Lymphoma Presenting As a Cavitary Mass in COVID-19 This case highlights the challenges of safely and expeditiously diagnosing and treating aggressive cancers of the respiratory tract in patients acutely infected with SARS-CoV-2.
Journal of Medical Case Reports, April 07, 2023
Premature Aging in Young Adult Survivors of Pediatric Cancer A new study assesses premature aging among pediatric cancer survivors as determined by a deficit accumulation index. Could this approach help identify those most at risk of age-related impairments?
Journal of the National Cancer Institute, March 16, 2023
Camrelizumab in Inoperable or Advanced NSCLC Patients A new study provides insight into the safety and effectiveness of camrelizumab in real world NSCLC patients with inoperable or advanced disease.
Translational Lung Cancer Research, March 10, 2023
Tools for Contralateral Prophylactic Mastectomy Decisions More women are opting to undergo this procedure to help reduce the risk of developing contralateral breast cancer. What tools are available to help them make an informed decision?
Journal of Clinical Oncology, January 25, 2023
Diagnosing EBV+ B- and T-Cell Lymphoproliferative Disorders This review and case series highlights the challenges of diagnosing Epstein-Barr virus-associated lymphoproliferative disorders, presenting guidance on accurate diagnosis.
American Journal of Clinical Pathology, January 25, 2023
Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer Is this drug therapy an effective therapeutic option for HR+/HER2- advanced breast cancer? What benefits might this treatment offer over single-agent chemotherapy?
Journal of Clinical Oncology, January 11, 2023
Radiotherapy Dose and Breast Cancer Risk Among HL Survivors Hodgkin lymphoma patients treated with radiotherapy are at an increased risk for developing breast cancer. Is this risk dose-dependent?
Journal of the National Cancer Institute, November 02, 2022
How I Diagnose Mature T-Cell Proliferations by Flow Cytometry Peripheral T-cell neoplasms can be diagnostically challenging. Using two illustrative cases, this paper reviews the application of flow cytometry to the interpretation of mature T-cell proliferations.
American Journal of Clinical Pathology, October 25, 2022
Severe Outcomes Among Immunocompromised Adults With COVID-19 This study found that immunocompromised patients accounted for over 12% of all adult COVID-19 hospitalizations and had increased odds of ICU admission and death, irrespective of vaccination status.
Morbidity & Mortality Weekly Report, September 28, 2022
Pembro-GVD for Relapsed or Refractory Hodgkin Lymphoma Should this regimen be considered as a second-line treatment option for patients with relapsed or refractory Hodgkin lymphoma?
Journal of Clinical Oncology, August 30, 2022
Management of HER2-Positive Metastatic Breast Cancer This article provides an overview of current treatment strategies and potential new therapeutic options for HER2-positive breast cancer in the metastatic setting.
Journal of Oncology Practice, August 23, 2022
T-DM1 vs Paclitaxel With Trastuzumab for HER2 Breast Cancer How do these two treatments for HER2-positive breast cancer compare in terms of side effects and survival outcomes?
Journal of Clinical Oncology, August 18, 2022
Factors for Thyroid Complications After Radiation Therapy How often do cancer patients experience thyroid complications after receiving radiation therapy, and what are the risk factors?
Clinical Endocrinology, April 29, 2022
Molecular Alterations and Immune Checkpoint Blockade Could certain genomic biomarkers predict response or resistance to immune checkpoint inhibitor treatment?
Journal of the National Cancer Institute, January 11, 2022
Immune Checkpoint Inhibitor Treatment Toxicity Risk in RA A new analysis investigates the potential for patients with rheumatoid arthritis to experience adverse events after treatment with immune checkpoint inhibitors.
Journal of Clinical Rheumatology, November 01, 2021

No Results